Payment overview · 2025
General Payments
We did not find matching Open Payments records for this doctor in the selected program year.
Healthcare provider profile · identity verified
Haris Bilal, M.D.
Internal Medicine · KEENE, NH · NPI 1821379512
Verified facts
What the public records show
We did not find matching Open Payments records for this doctor in 2025.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Analysis 1 · Payment-linked products
Products named in Open Payments records
No payment-linked product analysis is available because no matching General Payment records were found for the selected year.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
There is no payer-company set available for this comparison.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 98 |
| Eliquis | Apixaban | 344 | 41 |
| Trazodone Hcl | Trazodone Hcl | 305 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 40 |
| Furosemide | Furosemide | 254 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 44 |
| Gabapentin | Gabapentin | 222 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 35 |
| Lisinopril | Lisinopril | 183 | 31 |
| Mirtazapine | Mirtazapine | 171 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 32 |
| Sertraline Hcl | Sertraline Hcl | 145 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 38 |
| Donepezil Hcl | Donepezil Hcl | 115 | 20 |
| Potassium Chloride | Potassium Chloride | 108 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 25 |
| Metformin Hcl | Metformin Hcl | 93 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 33 |
| Warfarin Sodium | Warfarin Sodium | 92 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 23 |
| Finasteride | Finasteride | 87 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 12 |
| Losartan Potassium | Losartan Potassium | 77 | 16 |
| Lamotrigine | Lamotrigine | 73 | suppressed |
| Olanzapine | Olanzapine | 67 | suppressed |
| Aripiprazole | Aripiprazole | 58 | suppressed |
| Baclofen | Baclofen | 56 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Levetiracetam | Levetiracetam | 55 | 12 |
| Allopurinol | Allopurinol | 54 | suppressed |
| Jantoven | Warfarin Sodium | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Risperidone | Risperidone | 50 | 12 |
| Bupropion Xl | Bupropion Hcl | 49 | 11 |
| Omeprazole | Omeprazole | 47 | suppressed |
| Latanoprost | Latanoprost | 46 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Famotidine | Famotidine | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Enulose | Lactulose | 41 | suppressed |
| Torsemide | Torsemide | 41 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 24 |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Humalog | Insulin Lispro | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | suppressed |
| Prednisone | Prednisone | 32 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Anastrozole | Anastrozole | 24 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 12 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | 11 |
| Azithromycin | Azithromycin | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | 13 |
| Glipizide Er | Glipizide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | — | — | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error